Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Africa

Roche Basel Switzerland

Fresh approval for Roche’s Lucentis as competition heats up

Approved for more diabetes-related eye complications

- PMLiVE

Novo Nordisk confirms public listing for IT unit

Will spin off its NNIT business as a separate company

- PMLiVE

Sanofi launches inhaled insulin in US

Partners with MannKind on only diabetes treatment of its kind

- PMLiVE

Lilly and Boehringer claim first place for diabetes combination

US FDA backs Glyxambi as first combination of SGLT2 inhibitor and DPP-4 inhibitor.

- PMLiVE

Boehringer and Lilly sway NICE with new Jardiance data

Diabetes drug now backed to help glycaemic control in adults

- PMLiVE

Novo Nordisk’s Xultophy debuts in Switzerland

It is the first market for combination of diabetes treatments Tresiba and Victoza

- PMLiVE

Type 2 diabetes market in Asia-Pacific to hit $10.5bn by 2020

Analysts predict increase of $4bn from 2013 figure

- PMLiVE

FDA approval for Novo Nordisk’s obesity shot

New formulation of diabetes drug Victoza will be marketed as Saxenda

- PMLiVE

Cyramza gets FDA green light in lung cancer

Drug steadily being approved for further uses

UK flag

Education at heart of new UK diabetes guidelines

NICE recommends new standards for adults with type 1 and children with either type 1 or type 2

- PMLiVE

Sharing good diabetes practice in the NHS

Breaking down healthcare silos to demonstrate the benefits and adaptability of diabetes care initiatives

- PMLiVE

Diabetes puts economic growth at risk, says IDF

Comments come on World Diabetes Day

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links